ARGON GREEN VS KRYPTON RED LASER PHOTOCOAGULATION FOR EXTRAFOVEAL CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION - 3-YEAR RESULTS OF A MULTICENTER RANDOMIZED TRIAL
Ar. Willan et al., ARGON GREEN VS KRYPTON RED LASER PHOTOCOAGULATION FOR EXTRAFOVEAL CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION - 3-YEAR RESULTS OF A MULTICENTER RANDOMIZED TRIAL, Canadian journal of ophthalmology, 31(1), 1996, pp. 11-17
Objective: To determine whether argon green laser (AGL) or krypton red
laser (KRL) is superior for the treatment of well-defined extrafoveal
choroidal neovascularization (CNV) in patients with age-related macul
ar degeneration (AMD) after 3 years of follow-up. Design: Multicentre
randomized clinical trial. Setting: University-based referral practice
s in Canada. Participants: Among 210 patients selected by ophthalmolog
ists at 13 participating centres there were 191 eligible patients aged
50 years or more with angiographically proven CNV whose posterior edg
e was 200 to 2500 mu m from the foveal avascular zone. Other inclusion
criteria included the presence of drusen in either eye, a best correc
ted visual acuity in the study eye of at least 35 letters on the Early
Treatment Diabetic Retinopathy Study chart (equivalent of 20/200 or b
etter on the Snellen chart) and no prior photocoagulation in the study
eye. The patients were randomly assigned to receive either AGL (96 pa
tients) or KRL (95 patients) treatment. Interventions: Treatment with
200-mu m spots of 0.2 to 0.5 seconds' exposure to produce a homogeneou
s grey white lesion that completely covered the CNV. Outcome measures:
Change from baseline in visual acuity at 1, 2 and 3 years (primary me
asure), development of persistent or recurrent CNV (secondary measure)
. Results: There were no significant differences between the treatment
groups in drop-out rates, No significant differences were found betwe
en the two groups in loss of visual acuity or angiographic evidence of
persistent or recurrent CNV. Conclusion: KRL is no better than AGL in
preserving vision and preventing loss of visual acuity in patients wi
th AMD with well-defined extrafoveal CNV followed for 3 years.